← Back to Search

Immunomodulator

Abatacept for Interstitial Lung Disease (ATtackMy-ILD Trial)

Phase 2

Waitlist Available

Research Sponsored by Rohit Aggarwal, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 weeks

Awards & highlights

ATtackMy-ILD Trial Summary

This trial is testing whether a drug called Abatacept can treat interstitial lung disease associated with the anti-synthetase syndrome.

Eligible Conditions

Interstitial Lung Disease
Myositis

ATtackMy-ILD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Vital capacity

Secondary outcome measures

Dyspnea

Time to improvement in FVC% by ≥10

Time to progression free survival where progression

Side effects data

From 2023 Phase 3 trial • 613 Patients • NCT03086343

URINARY TRACT INFECTION

UPPER RESPIRATORY TRACT INFECTION

NASOPHARYNGITIS

HYPERTENSION

100%

80%

60%

40%

20%

Study treatment Arm

Abatacept

Upadacitinib 15 mg

ATtackMy-ILD Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: AbataceptExperimental Treatment1 Intervention

Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.

Group II: PlaceboPlacebo Group1 Intervention

Subcutaneous placebo injection weekly for 24 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Abatacept

2005

Completed Phase 4

~112150

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rohit Aggarwal, MDLead Sponsor

2 Previous Clinical Trials

146 Total Patients Enrolled

Bristol-Myers SquibbIndustry Sponsor

2,638 Previous Clinical Trials

4,128,494 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people will be given lenalidomide in this experiment?

"This particular clinical trial is no longer recruiting patients. It was first posted on June 1st, 2017 and last updated on October 31st, 2022. However, there are currently 326 trials for myositis and 36 trials for Abatacept that are still enrolling patients."

Answered by AI

What is the total number of research facilities participating in this project?

"Patients can be enrolled at this clinical trial at Brigham & Women's Hospital in Boston, Cedars-Sinai Medical Center in Beverly Hills, John Hopkins Medical Center in Baltimore. Including these 5 additional sites, there are a total of 10 locations where patients can enroll."

Answered by AI

To what condition does Abatacept lend itself as a treatment?

"Abatacept is an effective intervention for patients experiencing rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis."

Answered by AI

Could you please list any other research studies that have used Abatacept?

"Abatacept was first researched in 2007 by University of Nebraska Medical Center. Since that time, there have been a total of 18370 completed studies on the topic. Right now, there are 36 trials underway with some taking place in Boston, Massachusetts."

Answered by AI

Has the Abatacept drug been federally approved in the USA?

"Abatacept's safety is estimated to be a 2. This is due to the fact that it is still in Phase 2 trials, meaning while there are some studies that support its safety, none have been able to confirm its efficacy."

Answered by AI

Are there any more slots open for willing participants in this research?

"The clinical trial in question is not currently active, based on information from the website. This particular study was first posted on June 1st, 2017 and was last edited on October 31st, 2022. There are, however, 362 other trials that are looking for patients right now."

Answered by AI

Recent research and studies

Annals of the Rheumatic DiseasesJournal

Mode of Action of Abatacept in Rheumatoid Arthritis Patients Having Failed Tumour Necrosis Factor Blockade: A Histological, Gene Expression and Dynamic Magnetic Resonance Imaging Pilot Study

Buch, M H, D L Boyle, S Rosengren, B Saleem, R J Reece, L A Rhodes, A Radjenovic, et al.. 2008. “Mode of Action of Abatacept in Rheumatoid Arthritis Patients Having Failed Tumour Necrosis Factor Blockade: A Histological, Gene Expression and Dynamic Magnetic Resonance Imaging Pilot Study”. Annals of the Rheumatic Diseases. BMJ. doi:10.1136/ard.2008.091876.

European Journal of Medicinal ChemistryJournal

A New Series of Amodiaquine Analogues Modified in the Basic Side Chain with in Vitro Antileishmanial and Antiplasmodial Activity

Guglielmo, Stefano, Massimo Bertinaria, Barbara Rolando, Marco Crosetti, Roberta Fruttero, Vanessa Yardley, Simon L. Croft, and Alberto Gasco. 2009. “A New Series of Amodiaquine Analogues Modified in the Basic Side Chain with in Vitro Antileishmanial and Antiplasmodial Activity”. European Journal of Medicinal Chemistry. Elsevier BV. doi:10.1016/j.ejmech.2009.09.012.

JAMA Network OpenJournal

Risk of Thyroxine-treated Autoimmune Thyroid Disease Associated with Disease Onset in Patients with Rheumatoid Arthritis

Waldenlind, Kristin, Saedis Saevarsdottir, Camilla Bengtsson, and Johan Askling. 2018. “Risk of Thyroxine-treated Autoimmune Thyroid Disease Associated with Disease Onset in Patients with Rheumatoid Arthritis”. JAMA Network Open. American Medical Association (AMA). doi:10.1001/jamanetworkopen.2018.3567.

Clinical ImmunologyJournal